# Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

*PRI Rank #4 · Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026/rank-4*

| Field | Value |
| --- | --- |
| Rank | #4 |
| 18m citations | 97 |
| Journal | Journal of Clinical Oncology |
| Year | 2024 |
| DOI | 10.1200/jco.23.00137 |
| Corresponding authors | Dennis J Slamon |
| Institution | University of California Los Angeles, United States |

**Ranking page:** [Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026](https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026)

**Paper link:** [10.1200/jco.23.00137](https://doi.org/10.1200/jco.23.00137)

## Topics

palbociclib · letrozole · overall survival · progression-free survival · ER-positive breast cancer · HER2-negative breast cancer · advanced breast cancer · postmenopausal women · PALOMA-2 · CDK4/6 inhibitor · endocrine therapy · hazard ratio · survival outcome imbalance · median follow-up 90.1 months · first-line systemic therapy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cancer-related Molecular Pathways Papers, Class of 2026. https://pri.pepkio.com/top-papers/cancer-related-molecular-pathways/2026. Accessed 2026-10-28.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```